Investor's Business Daily on MSN2h
Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades DrugNeurocrine Biosciences stock jumped Monday after the biotech company won Food and Drug Administration approval for the first new treatment for an adrenal disease in decades. Please watch the video at ...
Kisspeptin-10, a decapeptide derived from the KISS1 gene, has emerged as a focal point of research due to its potential role ...
BBC Good Food on MSN10h
The best supplements, tried and testedConsidering taking a supplement? Read our guide to the various supplements on the market, plus our top-rated products in each ...
The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.
A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback